The study was conducted by researchers from Hong Kong University and involved patients who used NSAIDs for arthritis with ulcer bleeding. After their ulcers had healed, those who were negative for Helicobacter pylori were randomised to either 200 mg of celecoxib twice daily plus daily placebo or 75 mg of diclofenac twice daily plus 20 mg of omeprazole daily for six months.
The end point was recurrent ulcer bleeding. In the intention-to-treat analysis, which included 287 patients, recurrent ulcer bleeding occurred in 7 patients receiving celecoxib and 9 receiving diclofenac plus omeprazole. The probability of recurrent bleeding during the six-month period was 4.9% for patients who received celecoxib and 6.4% for patients who received diclofenac plus omeprazole.
Renal adverse events, including hypertension, peripheral oedema, and renal failure, occurred in 24.3% of patients on celecoxib and 30.8% of those receiving diclofenac plus omeprazole.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!